[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337838-105":59,"doc-detail-337838-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pre-treatment-peripheral-blood-immunophenotyping-and-response-to-neoadjuvant-chemotherapy-in-operable-breast-cancer","Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer","","Tumor immune infiltration and peripheral blood immune signatures carry prognostic and predictive value in breast cancer, yet the links between peripheral blood immune phenotypes and response to neoadjuvant chemotherapy (NAC) remain insufficiently studied. This study analyzes peripheral blood mononuclear cells from 126 patients using time-of-flight cytometry with 29 immune surface markers. Results show subtype-specific associations with pathologic complete response and residual disease in TNBC and hormone receptor-positive disease, but not in HER2-positive cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pre-treatment-peripheral-blood-immunophenotyping-and-response-to-neoadjuvant-chemotherapy-in-operable-breast-cancer/337838/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pre-treatment-peripheral-blood-immunophenotyping-and-response-to-neoadjuvant-chemotherapy-in-operable-breast-cancer/337838.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about peripheral blood immune phenotypes?","Question",{"text":112,"@type":113},"It evaluates whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy in operable breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were immune profiles measured in the study?",{"text":117,"@type":113},"Peripheral blood mononuclear cells from 126 patients were analyzed using cytometry by time-of-flight with a panel of 29 immune cell surface protein markers.",{"name":119,"@type":110,"acceptedAnswer":120},"Which breast cancer subtypes showed associations between pre-treatment immune cells and NAC response?",{"text":121,"@type":113},"Associations were found in early-stage TNBC and hormone receptor-positive breast cancer, while HER2-positive breast cancer showed no differences in immune phenotype by NAC response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337838,1790137756,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Leon‑Ferre et al. Breast Cancer Research (2024) 26:97  \n[https://doi.org/10.1](https://doi.org/10.1) 186/s13058‑024‑01848‑z  \nBreast Cancer Research  \n RESEARCH Open Access  \nPre‑treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer  \nRoberto A. Leon‑Ferre 1*, Kaitlyn R. Whitaker2, Vera J. Suman3, Tanya Hoskin3, Karthik V. Giridhar 1, Raymond M. Moore3, Ahmad Al‑Jarrad2, Sarah A. McLaughlin4, Donald W. Northfelt5, Katie N. Hunt6, Amy Lynn Conners6, Ann Moyer7, Jodi M. Carter8, Krishna Kalari3, Richard Weinshilboum9, Liewei Wang3, James N. Ingle 1, Keith L. Knutson 10, Stephen M. Ansell2, Judy C. Boughey 11, Matthew P. Goetz 1† and Jose C. Villasboas2†  \nAbstract  \nBackground Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neo‑ adjuvant chemotherapy (NAC) remains understudied.  \nMethods Peripheral blood mononuclear cells from 126 breast cancer patients enrolled in a prospective clinical trial (NCT02022202) were analyzed using Cytometry by time‑of‑flight with a panel of 29 immune cell surface protein markers. Kruskal–Wallis tests or Wilcoxon rank‑sum tests were used to evaluate differences in immune cell subpopula‑ tions according to breast cancer subtype and response to NAC.  \nResults There were 122 evaluable samples: 47 (38 . 5%) from patients with hormone receptor‑positive, 39 (32%) triple‑ negative (TNBC), and 36 (29 . 5%) HER2‑positive breast cancer. The relative abundances of pre‑treatment peripheral blood T, B, myeloid, NK, and unclassified cells did not differ according to breast cancer subtype. InTNBC, higher pre‑ treatment myeloid cells were associated with lower pathologic complete response (pCR) rates. In hormone receptor‑ positive breast cancer, lower pre‑treatment CD8 + naïve and CD4 +effector memory cells re‑expressing CD45RA (TEMRA) T cells were associated with more extensive residual disease after NAC. In HER2 + breast cancer, the peripheral blood immune phenotype did not differ according to NAC response.  \n\n| †Matthew P. Goetz and Jose C. Villasboas are co‑senior authors. |\n| --- |\n| Prior presentations: 2019 San Antonio Breast Cancer Symposium, 2020 American Society of Clinical Oncology Annual Meeting, and 2022 Association for Clinical and Translational Science Annual Meeting. |\n\n*Correspondence:  \nRoberto A. Leon‑Ferre  \n[leonferre. roberto@mayo.edu](leonferre. roberto@mayo.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)‑ [mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nLeon‑Ferre etal. Breas","cbCaiobkZgfyAlIO","https://ap.wps.com/l/cbCaiobkZgfyAlIO","pdf",2255701,11,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Trial registration\n# Keywords\n# Introduction","[{\"question\":\"What question does the study address about peripheral blood immune phenotypes?\",\"answer\":\"It evaluates whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy in operable breast cancer.\"},{\"question\":\"How were immune profiles measured in the study?\",\"answer\":\"Peripheral blood mononuclear cells from 126 patients were analyzed using cytometry by time-of-flight with a panel of 29 immune cell surface protein markers.\"},{\"question\":\"Which breast cancer subtypes showed associations between pre-treatment immune cells and NAC response?\",\"answer\":\"Associations were found in early-stage TNBC and hormone receptor-positive breast cancer, while HER2-positive breast cancer showed no differences in immune phenotype by NAC response.\"}]","Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer | PDF",1790020848,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69c0542fd49b5239b8f519212893f8cb.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0ee73d2aee6be1095f88c28cf51bdc6.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8acb5a69768b4d87447990c9b6501fc9.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86ca837c519b0062a220fa9fe30b4aed.webp",980,1301]